Pharmacoeconomy: an indispensable tool for the rationalization of health costs

Areda, Camila Alves; Bonizio, Roni Cleber; Freitas, Osvaldo de

doi:10.1590/s1984-82502011000200004

Cited by 12 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it has become imperative to conduct well-designed studies in the area of pharmaceutical care in order to obtain a clearer comprehension of its economic impact [ 14 ]. Well-designed studies investigating economic impact should be encouraged because they enable the rationalization of resources in health care, where the available resources are limited [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study

et al. 2015

View full text Add to dashboard Cite

BackgroundStudies have shown that pharmaceutical care can result in favorable clinical outcomes in human immunodeficiency virus (HIV)-infected patients, however, few studies have assessed the economic impact. The objective of this study was to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients.MethodsA controlled ambispective study was conducted in Brazil from January 2009 to June 2012. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes included expenses of physician and pharmaceutical appointments, laboratory tests, procedures, and hospitalizations, at six months and one year.ResultsIntervention and control groups included 51 patients each. We observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm3. None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures). An additional health care system daily investment of US$1.45, 1.09, 2.13, 4.35, 1.09, and 0.87 would be required for each additional outcome of viral load <50 copies/ml, absence of co-infection, CD4+ >200, 350, and 500 cells/mm3, and optimal immune response, respectively.ConclusionThis work demonstrated that pharmaceutical care of HIV-infected patients, for a one-year period, was able to decrease the number of pharmacotherapy problems. However, the clinical outcomes and the costs did not have statistical difference but showed higher percentage of better clinical outcomes and lower costs for some items.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…6 Os medicamentos consomem uma parcela considerável de recursos de um país, tendo um forte impacto sobre as despesas totais de saúde. 18 A aquisição de medicamentos requer gastos e se estes não forem bem assistidos por meio de uma assistência farmacêutica eficiente e eficaz, prováveis perdas serão inevitáveis, com aumento nos gastos e implicação no acesso. 19 Há um retorno financeiro positivo de nove a treze vezes quando o farmacêutico atua na UTI.…”

Section: Discussionunclassified

Análise das intervenções farmacêuticas associadas a custos evitáveis com a farmacoterapia em um hospital de ensino de Sergipe (Brasil) nos primeiros meses da Covid-19

OLIVEIRA¹,

ANDRADE²,

Cardoso³

et al. 2021

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

Objetivo: avaliar a repercussão das intervenções farmacêuticas nos custos evitáveis com a farmacoterapia em um hospital de ensino nos primeiros meses da Covid-19. Métodos: Estudo transversal retrospectivo, com abordagem quantitativa realizado em um hospital de ensino. Os dados avaliados foram obtidos a partir da documentação das intervenções realizadas entre abril e outubro de 2020 pelos farmacêuticos clínicos da instituição. Para calcular o custo inicial estimado e o custo final do tratamento foram considerados o valor do medicamento e os insumos utilizados para a sua administração multiplicado pela posologia (frequência e tempo de tratamento prescrito). Para a obtenção do valor economizado a cada intervenção subtraiu-se do valor inicial estimado do tratamento o custo final obtido. Resultados: foram registradas 167 intervenções farmacêuticas com redução de custos, gerando uma economia correspondente a $ 9.067,83. As unidades que mais demandaram intervenções farmacêuticas foram as Unidades de Terapia Intensiva (UTI) geral e Covid-19. Os antimicrobianos se destacaram com o maior número de intervenções relacionadas à redução de custo e com o maior montante economizado. Quanto ao tipo de intervenção relacionada à redução de custos, a mais frequente foi a redução de dose devido à alteração da função renal (49,48%). Conclusão: As intervenções farmacêuticas atuam como ferramenta para a promoção do uso racional de medicamentos pelos benefícios clínicos e econômicos. Este estudo permitiu demonstrar que o serviço farmacêutico, pode colaborar para a diminuição de gastos desnecessários na saúde.

show abstract

“…Since the early 1990s, in Australia and Canada, and especially with the establishment in the United Kingdom of the British National Institute for Health and Clinical Excellence in 1999, known as NICE, which includes evaluation in the selection of health innovations, the adoption of economic evaluation in decision-making has become an imminent necessity, to which an appropriate response of a practical and applicable nature must be given [3]. DOI In this sense, pharmacoeconomy [4] seems to emerge, becoming a cardinal discipline in the health scenario. Pharmacoeconomy provides professionals with information on all the economic aspects in the health sector, providing them with a broader perspective in the analysis of all the implications of the drug through specific methodological tools.…”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomics as a Management and Financial Strategy in Healthcare and Simulation as a Decision Making Tool for It The Case of Ozone Therapy

Remondino

Franzini

2018

International Journal of Simulation: Systems, Science &Amp; Technology

View full text Add to dashboard Cite

Pharmacoeconomics can play a very important role in decision-making for healthcare structures. In fact, it consists of economic evaluation of drugs and treatments for specific diseases. Several techniques exist for this, mainly based on traditional management and financial methods as, for example: cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis or cost-utility analysis. The present paper proposes the use of agent based process simulation as an additional tool to assess the pharmacoeconomic analysis, in which to incorporate traditional financial tools. This technique allows to compare different treatments ceteris paribus, that is by simulating the effects of different drugs and treatments on the same patient, by comparing both the medical effects and the economic and financial effects. Last, the paper proposes the case of ozone therapy as a powerful use case for this simulative approach, since ozone, a natural gas with antibacterial and anti-inflammatory properties, can successfully be used to treat many diseases as an alternative to other drugs and treatments.

show abstract

Pharmacoeconomy: an indispensable tool for the rationalization of health costs

Cited by 12 publications

References 26 publications

Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study

Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study

Análise das intervenções farmacêuticas associadas a custos evitáveis com a farmacoterapia em um hospital de ensino de Sergipe (Brasil) nos primeiros meses da Covid-19

Pharmacoeconomics as a Management and Financial Strategy in Healthcare and Simulation as a Decision Making Tool for It The Case of Ozone Therapy

Contact Info

Product

Resources

About